Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases.
The authors studied complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases (LM). One hundred twenty consecutive patients with LM (71 females and 49 males) ranging in age from 10 to 72 years (median 42 years) were treated with involved-field radiotherapy and intraventricular chemotherapy using an Ommaya reservoir and intraventricular catheter system. The diagnosis of LM was determined by a combination of clinical presentation (114 patients); cerebrospinal fluid cytological studies (100); or neuroradiographic studies (42). Systemic tumor histological findings included breast (34 patients); non-Hodgkin's lymphoma (22); melanoma (16); primitive neuroectodermal tumors including medulloblastoma (10); glial neoplasms, leukemia, small cell lung, nonsmall cell lung, and colon (six each); prostate and kidney (three each); and gastric cancers (two). Sixteen patients, all with non-Hodgkin's lymphoma, also had acquired immune deficiency syndrome. Patients received one to four (median two) chemotherapeutic drugs and underwent a total of 1110 cycles of intraventricular chemotherapy (median 10). Intraventricular chemotherapy administration and diagnostic Ommaya reservoir punctures totaled 4400, with a median of 46 per patient. Complications included aseptic/chemical meningitis (52 patients); myelosuppression due to intraventricular chemotherapy (21); catheter-related infections (nine); unidirectional catheter obstruction (six); intraventricular catheter malpositioning (two); Ommaya reservoir exposure (two); leukoencephalopathy (two); and chemotherapy-related myelopathy (one). There were no treatment-related deaths; however, seven patients (6%) required additional surgery for either catheter repositioning (two) or reservoir removal (five). Seven patients with catheter-related infections were treated successfully with intraventricular and systemic antibiotic drugs, thereby preserving the Ommaya system. The authors conclude that Ommaya reservoirs are convenient and pharmacologically rational systems for administering intraventricular chemotherapy. Overall, serious complications requiring surgery are infrequent (6%) and most often secondary to catheter infections, Ommaya reservoir exposure, or initial catheter malpositioning. In the majority of instances, catheter infections may be managed medically, as may the most common complications of intraventricular chemotherapy including aseptic meningitis (43% of patients) and myelosuppression (18%).
Chamberlain
M C
MC
Department of Neurosciences, University of California at San Diego, 92093-8421, USA.
Kormanik
P A
PA
Barba
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects*; D002408:Catheters, Indwelling / Q000009:adverse effects; D002552:Cerebral Ventricles; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems / Q000009:adverse effects* / Q000295:instrumentation*; D005260:Female; D006801:Humans; D007322:Instillation, Drug; D008297:Male; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008581:Meningitis / Q000139:chemically induced / Q000209:etiology* / Q000382:microbiology; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D013852:Thiotepa / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D003561:Cytarabine; D013852:Thiotepa; D008727:Methotrexate